Semaglutide in aged female mice: lifespan and ageing markers
A description of a study in aged female mice reports that late-life semaglutide improved cognition, physical function and glucose control and raised median lifespan from 742 to 834 days. This is animal evidence, not a human lifespan benefit. [1]
Automatic summary · not editorially reviewed
The key findings
In aged female mice, late-life semaglutide was described as improving cognition, physical function and glucose control and as attenuating multiple hallmarks of ageing. [1]
The creator suggests semaglutide may act partly as a calorie-restriction mimetic, with nutrient sensing, NAD⁺–sirtuin and insulin–IGF1 pathways implicated. [1]
Median lifespan in the described mice increased from 742 to 834 days. [1]
The source at a glance
- Study type / format
- Video description of an animal study in aged female mice.
- Population / context
- Aged female mice in a study described in the video description.
- Summary based on
- Creator description
- Original publication
- September 3, 2026
Aged female mice given semaglutide late in life
The description presents a study in aged female mice. Semaglutide was given late in life, and the creator suggests it may act partly as a calorie-restriction mimetic. The described biology involves nutrient sensing, NAD⁺–sirtuin and insulin–IGF1 pathways. The description does not report the dose, the comparison group or how long the animals were followed.
Supporting source [1]
Reported gains in cognition, function and glucose control
According to the description, semaglutide improved cognition, physical function and glucose control in these aged female mice and attenuated multiple hallmarks of ageing. The description does not say how each of these outcomes was measured or how large the changes were. These are described associations in animals, not proof that semaglutide slows ageing in people.
Supporting source [1]
Median lifespan rose from 742 to 834 days in mice
The description calls the lifespan result most striking: median lifespan increased from 742 to 834 days. It gives no information on statistical uncertainty, maximum lifespan or cause of death. The findings come from aged female mice only, so they cannot be transferred to human lifespan or to people with obesity or diabetes.
Supporting source [1]
How to interpret this
This is a video description only; the video and transcript were not reviewed. The description gives no dose, comparison group, follow-up, uncertainty or measurement details, and the results are from aged female mice, not humans.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
MasterMedFacts · youtube.com · September 3, 2026